Earnings Feed
Start Free
Home/Filings/4/0001225208-11-011353
4//SEC Filing

CSIMMA ZOLTAN A 4

Accession 0001225208-11-011353

CIK 0000732485other
View on SEC.govCompany Profile

Filed

Apr 5, 8:00 PM ET

Accepted

Apr 6, 11:44 AM ET

Size

39.5 KB

Accession

0001225208-11-011353

Insider Transaction Report

Form 4
Period: 2011-04-04
GENZYME CORPGENZ
CSIMMA ZOLTAN A
SrVP,Chief Human Resources Off
Transactions
  • Disposition to Issuer

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−125$9,250→ 18,620 total
  • Disposition to Issuer

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−5,640$417,360→ 12,980 total
  • Exercise/Conversion

    Restricted Stock Units

    2011-04-04−3,695→ 0 total
    From: 2010-05-21→ Genzyme common stock (GENZ) (3,695 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$62.98/sh−35,000$2,204,300→ 0 total
    Exercise: $62.98From: 2005-05-26Exp: 2015-05-26→ Genzyme common stock (GENZ) (35,000 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+3,695→ 16,800 total
  • Disposition from Tender

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−12,980$960,520→ 0 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$58.66/sh−16,625$975,223→ 0 total
    Exercise: $58.66From: 2009-05-21Exp: 2019-05-21→ Genzyme common stock (GENZ) (16,625 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$68.48/sh−17,500$1,198,400→ 0 total
    Exercise: $68.48From: 2008-05-22Exp: 2018-05-22→ Genzyme common stock (GENZ) (17,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$62.16/sh−17,500$1,087,800→ 0 total
    Exercise: $62.16From: 2007-05-24Exp: 2017-05-24→ Genzyme common stock (GENZ) (17,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$41.50/sh−578$23,987→ 0 total
    Exercise: $41.50From: 2002-05-30Exp: 2012-05-30→ Genzyme common stock (GENZ) (578 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+1,945→ 18,745 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$51.52/sh−16,625$856,520→ 0 total
    Exercise: $51.52Exp: 2020-06-16→ Genzyme common stock (GENZ) (16,625 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$46.24/sh−27,000$1,248,480→ 0 total
    Exercise: $46.24From: 2003-05-29Exp: 2013-05-29→ Genzyme common stock (GENZ) (27,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$32.52/sh−54,825$1,782,909→ 0 total
    Exercise: $32.52From: 2002-05-30Exp: 2012-05-30→ Genzyme common stock (GENZ) (54,825 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$32.52/sh−12,300$399,996→ 0 total
    Exercise: $32.52From: 2005-05-30Exp: 2012-05-30→ Genzyme common stock (GENZ) (12,300 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2011-04-04−1,945→ 1,944 total
    From: 2009-05-22→ Genzyme common stock (GENZ) (1,945 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$58.50/sh−35,000$2,047,500→ 0 total
    Exercise: $58.50From: 2006-05-25Exp: 2016-05-25→ Genzyme common stock (GENZ) (35,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$43.90/sh−41,000$1,799,900→ 0 total
    Exercise: $43.90From: 2004-05-27Exp: 2014-05-27→ Genzyme common stock (GENZ) (41,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$53.47/sh−24,000$1,283,280→ 0 total
    Exercise: $53.47From: 2001-05-31Exp: 2011-05-31→ Genzyme common stock (GENZ) (24,000 underlying)
Footnotes (2)
  • [F1]The vested restricted stock units were scheduled to be released on 5/22/2011 and 5/21/2012.
  • [F2]This option, which provided for vesting 20% at grant and 20% annually over four years, was cancelled upon the consummation of the sanofi-aventis tender offer in exchange for a payment representing (A) an amount of cash equal to the excess of $74.00 over the exercise price of the option, multiplied by the total number of shares subject to such options, and (B) one contingent value right (CVR) per cancelled option.

Documents

1 file

Issuer

GENZYME CORP

CIK 0000732485

→
Entity typeother

Related Parties

1
  • filerCIK 0001201255

Filing Metadata

Form type
4
Filed
Apr 5, 8:00 PM ET
Accepted
Apr 6, 11:44 AM ET
Size
39.5 KB
View on SEC.gov